{"product_id":"pwmedtech-pestle-analysis","title":"PW Medtech Group PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, regulatory pressures, and technological advances are reshaping PW Medtech Group’s prospects—our concise PESTLE highlights the risks and opportunities that matter to investors and strategists; buy the full analysis to access the complete, actionable breakdown and downloadable templates for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare reform policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Healthy China 2030 plan and renewed push for universal health coverage are accelerating hospital upgrades and demand for domestic medtech; government R\u0026amp;D subsidies and procurement preferences lifted Chinese medtech investment to RMB 120bn in 2024, benefiting PW Medtech’s interventional devices as hospital procedure volumes grew ~8% YoY, directly supporting the company’s long-term volume and market-penetration strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical trade tensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing China-West trade friction disrupts access to high-end raw materials and specialized equipment, raising component costs for PW Medtech’s cardiovascular and orthopedic lines—e.g., semiconductor and titanium supply tightness pushed input prices up ~8–12% in 2024 for medical-device suppliers. Export controls and potential tariffs could add 5–15% to bill-of-materials costs, while political instability in target markets risks derailing planned 20–30% revenue growth from overseas expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized procurement expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe expansion of China’s Volume-Based Procurement (VBP) since 2023 has driven price cuts up to 60% for selected medical devices, reshaping competition and pressuring margins on high-volume items such as stents and orthopedic implants where PW Medtech earns ~45% of sales.\u003c\/p\u003e\n\u003cp\u003eGuaranteed hospital volumes from VBP force PW Medtech to accept lower unit prices—management reported a 12% gross margin compression in 2024 for VBP-participating SKUs—necessitating tighter cost control.\u003c\/p\u003e\n\u003cp\u003eTo retain market share in the \u0026gt;70% hospital procurement channel, PW Medtech must adapt pricing to state bidding cycles, optimize manufacturing scale, and target non-VBP niche products to preserve overall profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupport for domestic substitution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical mandates promoting Made in China medical devices give PW Medtech a measurable advantage: government procurement policies raised domestic share in public hospital device purchases to 62% in 2024, up from 51% in 2020, favoring local suppliers over multinationals.\u003c\/p\u003e\n\u003cp\u003eLocal governments offer subsidies and preferential hospital quotas—some provinces provide up to 15% price subsidies or procurement preference for domestic cardiovascular and orthopedic devices—enabling PW Medtech to reclaim market share from global incumbents.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2024 domestic procurement share 62%\u003c\/li\u003e\n\u003cli\u003eProvincial subsidies up to 15%\u003c\/li\u003e\n\u003cli\u003eMarket share gains vs multinationals in cardiovascular\/orthopedics\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory alignment with global standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe NMPA’s continued alignment with IMDRF frameworks has cut average device approval times by about 20% since 2018, accelerating PW Medtech’s go‑to‑market for exportable devices and easing technology transfers for joint ventures.\u003c\/p\u003e\n\u003cp\u003eHarmonization reduces regulatory duplication and lowers market-entry costs, supporting PW Medtech’s overseas expansion and licensing deals.\u003c\/p\u003e\n\u003cp\u003eConcurrently, heightened political oversight on clinical data integrity has driven a 15–25% rise in compliance and QA spending across Chinese medtech firms, forcing PW Medtech to boost related CAPEX and audit capacity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproval times down ~20% since 2018\u003c\/li\u003e\n\u003cli\u003eCompliance\/QA costs up 15–25%\u003c\/li\u003e\n\u003cli\u003eImproved ease for overseas entry and tech transfers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina policy reshapes device market: 62% local share, margins squeezed ~12%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical drivers—Healthy China 2030, VBP expansion, Made-in-China procurement and NMPA-IMDRF alignment—raised domestic hospital device share to 62% in 2024, cut approvals ~20% since 2018, but pushed compliance costs up 15–25% and drove 8–12% input price inflation from trade frictions, compressing VBP SKU gross margins ~12% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic procurement share\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval time change since 2018\u003c\/td\u003e\n\u003ctd\u003e-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\/QA cost rise\u003c\/td\u003e\n\u003ctd\u003e15–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput price inflation\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP SKU margin compression\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal forces uniquely impact PW Medtech Group, with each section drawing on current market data and regional regulatory dynamics to identify risks and growth opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, PESTLE-segmented brief that highlights external risks and opportunities for PW Medtech Group, enabling quick inclusion in presentations, collaborative planning, or consultant reports while allowing users to add region- or product-specific notes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare spending growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising GDP and a 2024 per capita disposable income of about CNY 36,000 in China support higher healthcare spending, driving demand for PW Medtech’s cardiovascular and orthopedic devices as elective procedures grow. Affluent patients increasingly opt for advanced interventions, with China’s healthcare expenditure rising to ~7.1% of GDP in 2023, expanding market opportunities. Economic growth in lower-tier cities—where disposable income rose faster than national average in 2023—fuels demand as infrastructure and hospital upgrades reach underserved regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost pressure from VBP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe economic reality of Volume-Based Procurement has driven price erosion up to 40-60% for mature device categories in China by 2024, pressuring PW Medtech’s margins.\u003c\/p\u003e\n\u003cp\u003eTo remain profitable under lower tender prices the company must cut manufacturing costs and boost supply-chain efficiency; industry targets show 10-15% cost-to-serve reductions achievable via automation and local sourcing.\u003c\/p\u003e\n\u003cp\u003eDiversification into non-VBP high-margin innovative products—where gross margins often exceed 60%—is critical for economic survival given VBP-driven revenue squeezes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePW Medtech’s international exposure makes Renminbi volatility versus the US dollar and euro material: a 5% RMB depreciation in 2024 would raise imported component costs by roughly the same magnitude, squeezing gross margins, while a 3–7% RMB appreciation in 2023–24 periods improved export competitiveness for select product lines; FX swings also produced non-operating FX losses of $4–7 million across comparable peers during 2023–24, a risk to net income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and capital access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe prevailing interest rate environment in 2025–2026 raises PW Medtech’s average borrowing cost; global policy rates rose to about 4.5% (Fed funds) in 2024–25, lifting corporate yields and increasing project debt service burdens for R\u0026amp;D and facility expansion.\u003c\/p\u003e\n\u003cp\u003eAccess to low-cost capital remains critical: recent medtech deals saw leverage at 4–6x EBITDA, and higher rates could derail acquisitions or delay a planned €80–120m manufacturing buildout, while easing monetary policy would restore capacity for leveraged buyouts and capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024–25 policy rates ~4–4.5% impacting borrowing costs\u003c\/li\u003e\n\u003cli\u003eTypical sector leverage 4–6x EBITDA for acquisitions\u003c\/li\u003e\n\u003cli\u003ePlanned capex range €80–120m sensitive to rate shifts\u003c\/li\u003e\n\u003cli\u003eMonetary easing would enable renewed M\u0026amp;A and capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary impact on production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePW Medtech faces rising labor and input costs—global manufacturing wages grew ~6% in 2024 and metal\/plastic prices rose ~8–12% year-on-year—pushing up COGS while government tender pricing remains constrained.\u003c\/p\u003e\n\u003cp\u003eTo protect margins, the company must scale automation and lean manufacturing; capital expenditure on robotics can cut labor needs by 20–30% and improve unit costs amid 4–6% CPI-driven inflation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLabor inflation ~6% (2024); raw material +8–12% YoY\u003c\/li\u003e\n\u003cli\u003eGovernment procurement exerts downward pricing pressure\u003c\/li\u003e\n\u003cli\u003eAutomation\/lean can reduce labor costs 20–30%\u003c\/li\u003e\n\u003cli\u003eTarget efficiency to offset 4–6% CPI impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina medtech: demand rises but VBP cuts, cost inflation \u0026amp; FX\/rate risks squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic growth (China GDP +5.2% in 2024) and CNY36,000 per-capita disposable income boost elective procedure demand, while VBP-driven price erosion (40–60%) and input inflation (labor +6%, materials +8–12% in 2024) squeeze margins; RMB volatility (±5% in 2024) and higher rates (~4–4.5% 2024–25) raise FX and financing risks, making automation, local sourcing and high-margin product diversification essential.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina GDP growth\u003c\/td\u003e\n\u003ctd\u003e+5.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisposable income\u003c\/td\u003e\n\u003ctd\u003eCNY 36,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP price erosion\u003c\/td\u003e\n\u003ctd\u003e40–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabor inflation\u003c\/td\u003e\n\u003ctd\u003e+6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaterials\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolicy rates\u003c\/td\u003e\n\u003ctd\u003e4–4.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMB swing\u003c\/td\u003e\n\u003ctd\u003e±5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePW Medtech Group PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PW Medtech Group PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751863857529,"sku":"pwmedtech-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/pwmedtech-pestle-analysis.png?v=1772235490","url":"https:\/\/matrixbcg.com\/products\/pwmedtech-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}